구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, Capecitabine,Trastuzumab, and Pertuzumab) Shandong Cancer Hospital and Insti…·Metastatic Breast Cancer 1 trials |
|---|---|
Overview Program | Capecitabine,Trastuzumab, and Pertuzumab |
Overview Company | Shandong Cancer Hospital and Institute |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Breast Cancer |
Overview Indication | Metastatic Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | [A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].. Objective: To explore the application and efficacy of paclitaxel liposome in the treatment of advanced breast cancer among Chinese population in the real world. Methods: The clinical characteristics of patients with advanced breast cancer who received paclitaxel liposome as salvage treatment… |
Clinical Safety signal | [A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].. Objective: To explore the application and efficacy of paclitaxel liposome in the treatment of advanced breast cancer among Chinese population in the real world. Methods: The clinical characteristics of patients with advanced breast cancer who received paclitaxel liposome as salvage treatment… |
Clinical Selected reported efficacy | ORR 30% |
Clinical Reported ORR | 30.0% |
Clinical Result source | ClinicalTrials.gov NCT01026142 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01026142 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, Capecitabine,Trastuzumab, and Pertuzumab) Shandong Cancer Hospital and Insti…·Metastatic Breast Cancer 1 trials |
|---|---|
Overview Program | Capecitabine,Trastuzumab, and Pertuzumab |
Overview Company | Shandong Cancer Hospital and Institute |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Breast Cancer |
Overview Indication | Metastatic Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | [A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].. Objective: To explore the application and efficacy of paclitaxel liposome in the treatment of advanced breast cancer among Chinese population in the real world. Methods: The clinical characteristics of patients with advanced breast cancer who received paclitaxel liposome as salvage treatment… |
Clinical Safety signal | [A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].. Objective: To explore the application and efficacy of paclitaxel liposome in the treatment of advanced breast cancer among Chinese population in the real world. Methods: The clinical characteristics of patients with advanced breast cancer who received paclitaxel liposome as salvage treatment… |
Clinical Selected reported efficacy | ORR 30% |
Clinical Reported ORR | 30.0% |
Clinical Result source | ClinicalTrials.gov NCT01026142 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01026142 |
추천 비교
추천 비교